Abeona Therapeutics to Present at Phacilitate Cell & Gene Therapy World 2017
January 17 2017 - 7:53AM
Abeona Therapeutics Inc. (NASDAQ:ABEO) a clinical-stage
biopharmaceutical company focused on developing therapies for
life-threatening rare genetic diseases, today announced President
and CEO, Timothy J. Miller, Ph.D., will present and participate in
a panel discussion at the Phacilitate Cell & Gene Therapy World
2017 Conference in Miami, FL.
The following are the specific details regarding Abeona
Therapeutics Presentation & Panel Discussion:
Presentation: Therapeutic Area Clinical Update: CNS
- Case Study 4Date:
Friday, January 20th, 2017Time: 12:40 pm EST
Location: Miami, FL Website:
http://www.bioleaders-forum.com/conferences
Panel: Translational Academy:
Where it possible to do higher impact novel biotherapeutic
research today – academia or
industry?Date: Thursday, January 19th,
2017Panel Timing: 1:45 pm EST Panelists
Include: Timothy J. Miller, PhD, President & CEO,
Abeona Therapeutics Inc.J. Joseph Melenhorst, PhD, Director of
Product Development & Correlative Sciences, Center for Cellular
Immunotherapies, University of PennsylvaniaGreg Bonfiglio, Founder
& Managing Partner, Proteus, LLCOlivier Danos, SVP,
BiogenModerator: Dr Shashi Murthy, Professor,
Northeastern University
About Abeona: Abeona
Therapeutics Inc. is a clinical-stage biopharmaceutical company
developing gene therapies for life-threatening rare genetic
diseases. Abeona's lead programs include ABO-102 (AAV-SGSH) and
ABO-101 (AAV-NAGLU), adeno-associated virus (AAV) based gene
therapies for Sanfilippo syndrome (MPS IIIA and IIIB,
respectively). Abeona is also developing EB-101 (gene-corrected
skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB),
EB-201 for epidermolysis bullosa (EB), ABO-201 (AAV-CLN3) gene
therapy for juvenile Batten disease (JNCL), ABO-202 (AAV-CLN1) gene
therapy for treatment of infantile Batten disease (INCL), and
ABO-301 (AAV-FANCC) for Fanconi anemia (FA) disorder and ABO-302
using a novel CRISPR/Cas9-based gene editing approach to gene
therapy for rare blood diseases. In addition, Abeona has a
plasma-based protein therapy pipeline, including SDF Alpha™
(alpha-1 protease inhibitor) for inherited COPD, using its
proprietary SDF™ (Salt Diafiltration) ethanol-free process. For
more information, visit www.abeonatherapeutics.com.
This press release contains certain statements
that are forward-looking within the meaning of Section 27a of the
Securities Act of 1933, as amended, and that involve risks and
uncertainties. These statements are subject to numerous risks and
uncertainties, including but not limited to continued interest in
our rare disease portfolio, our ability to enroll patients in
clinical trials, the impact of competition; the ability to develop
our products and technologies; the ability to achieve or obtain
necessary regulatory approvals; the impact of changes in the
financial markets and global economic conditions; and other risks
as may be detailed from time to time in the Company's Annual
Reports on Form 10-K and other reports filed by the Company with
the Securities and Exchange Commission. The Company undertakes no
obligations to make any revisions to the forward-looking statements
contained in this release or to update them to reflect events or
circumstances occurring after the date of this release, whether as
a result of new information, future developments or otherwise.
Investor Contact:
Christine Berni-Silverstein
Vice President, Investor Relations
Abeona Therapeutics Inc.
+1 (212)-786-6212
csilverstein@abeonatherapeutics.com
Media Contact:
Andre’a Lucca
Vice President, Communications & Operations
Abeona Therapeutics Inc.
+1 (212)-786-6208
alucca@abeonatherapeutics.com
Abeona Therapeutics (NASDAQ:ABEO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Abeona Therapeutics (NASDAQ:ABEO)
Historical Stock Chart
From Apr 2023 to Apr 2024